Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: History and scenario of patient blood management in the world and in Brazil.

Patient Blood Management (PBM) is a multidimensional approach that seeks to optimize the use of blood and its components in patients. This matter emerged as a response to the need to reduce unnecessary exposure to blood transfusions and their potential risks. In the past, blood transfusion was often overused resulting in complications and high costs. The advent of Patient Blood Management has caused a paradigm shift, highlighting anemia prevention, bleeding control and maximizing the production of blood cells by the organism itself. Patient Blood Management guidelines include the early identification of anemia, strategies to minimize blood loss during surgery, intraoperative blood conservation techniques, preoperative hemoglobin optimization and evidence-based approaches to the rational use of blood transfusions. Aiming to improve clinical outcomes, decrease transfusion-related complications and reduce associated costs, this multidisciplinary approach counts on doctors, nurses, pharmacists and other healthcare professionals. Based on research and clinical evidence, Patient Blood Management continues to evolve thereby promoting safer, more effective patient-centered practices. Its implementation has proven beneficial in various medical contexts thereby contributing to improvements in the quality of care provided to patients. Our goal with this Consensus is to present readers with a broad and diverse view of Patient Blood Management so that they have the building blocks to implement this new technique.

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: Definition of Patient Blood Management.

Managing the patient's blood and hematopoietic system is like managing any of the other organs and organ systems during patient care. Specialists control the heart, kidneys, endocrine system, etc. and the patient's blood requires similar clinical treatment. The hematopoietic system and its circulatory products are fundamental for the healthy functioning of the human body. In simple terms, Patient Blood Management (PBM) is an organized, patient-centered approach in which the entire healthcare team coordinates efforts to improve outcomes by managing and preserving the patient's own blood. By reducing dependence on blood transfusions, PBM seeks to improve clinical outcomes, reduce the risks and costs associated with transfusions, and improve the safety and quality of patient care. Essentially, the concept of PBM is about the holistic management and preservation of the patient's own blood in the medical and surgical context.

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: Implementation of Patient Blood Management (PBM).

Patient Blood Management (PBM) is a holistic approach to managing blood as a resource of each patient; it is a multimodal strategy that is implemented using a set of techniques that can be applied in individual cases. In fact, the overall result of the implementation of PBM cannot be fully appreciated or explained by simply summing up the effects of the individual strategies and techniques used, since they can only produce the expected ideal result if combined. Implementing a PBM program in healthcare offers several benefits including improved patient safety, better outcomes, cost savings, conservation of resources, evidence-based practice, transfusion alternatives, improved quality of care, compliance with accreditation standards, patient-centered care, and professional education and training.

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: History and scenario of patient blood management in the world and in Brazil

Abstract Patient Blood Management (PBM) is a multidimensional approach that seeks to optimize the use of blood and its components in patients. This matter emerged as a response to the need to reduce unnecessary exposure to blood transfusions and their potential risks. In the past, blood transfusion was often overused resulting in complications and high costs. The advent of Patient Blood Management has caused a paradigm shift, highlighting anemia prevention, bleeding control and maximizing the production of blood cells by the organism itself. Patient Blood Management guidelines include the early identification of anemia, strategies to minimize blood loss during surgery, intraoperative blood conservation techniques, preoperative hemoglobin optimization and evidence-based approaches to the rational use of blood transfusions. Aiming to improve clinical outcomes, decrease transfusion-related complications and reduce associated costs, this multidisciplinary approach counts on doctors, nurses, pharmacists and other healthcare professionals. Based on research and clinical evidence, Patient Blood Management continues to evolve thereby promoting safer, more effective patient-centered practices. Its implementation has proven beneficial in various medical contexts thereby contributing to improvements in the quality of care provided to patients. Our goal with this Consensus is to present readers with a broad and diverse view of Patient Blood Management so that they have the building blocks to implement this new technique.

Consensus of the Brazilian association of hematology, hemotherapy and cellular therapy on patient blood management: Definition of Patient Blood Management

Abstract Managing the patient's blood and hematopoietic system is like managing any of the other organs and organ systems during patient care. Specialists control the heart, kidneys, endocrine system, etc. and the patient's blood requires similar clinical treatment. The hematopoietic system and its circulatory products are fundamental for the healthy functioning of the human body. In simple terms, Patient Blood Management (PBM) is an organized, patient-centered approach in which the entire healthcare team coordinates efforts to improve outcomes by managing and preserving the patient's own blood. By reducing dependence on blood transfusions, PBM seeks to improve clinical outcomes, reduce the risks and costs associated with transfusions, and improve the safety and quality of patient care. Essentially, the concept of PBM is about the holistic management and preservation of the patient's own blood in the medical and surgical context.

In vitro and in vivo validation of stored swine erythrocyte viability to establish an experimental model of homologous red blood cell transfusion: a pilot study.

OBJECTIVE: To develop experimental models of erythrocyte transfusion, the first step is to ensure the viability of the red blood cells transfused. In this pilot study, we assessed the viability of transfused red blood cells with validation in vitro and in vivo of homologous swine erythrocytes stored for 14 days. METHODS: Blood collected from one Agroceres swine was stored in two red blood cell units. In vivo validation was performed by labeling the red blood cells with Na25¹CrO4 and recovering the viable erythrocytes after 24 hours of infusion in one autologous and four homologous animals. In vitro validation was performed at baseline and after 14 days in sixteen red blood cell units by measuring hemoglobin, hematocrit, hemolysis index and free hemoglobin. A post-mortem splenectomy was performed to evaluate the splenic sequestration of erythrocytes, and the radioactivity of the supernatant samples was counted to evaluate intravascular hemolysis. RESULTS: After 14 days of storage, the red blood cell units had lower volumes and equivalent total concentrations of hemoglobin and hematocrit compared to human standards. The free hemoglobin concentration increased from 31.0±9.3 to 112.4±31.4 mg/dL (p<0.001), and the hemolysis index increased from 0.1±0.1 to 0.5±0.1% (p<0.001). However, these tests were within the acceptable range for human standards. The percentage of radioactivity in supernatant samples was similar at baseline and after 24 hours, thus excluding significant hemolysis. No evidence of splenic sequestration of radioactive erythrocytes was found. CONCLUSION: Swine red blood cells stored for 14 days are viable and can be used in experimental studies of transfusion. These validation experiments are important to aid investigators in establishing experimental models of transfusion.

Validação in vitro e in vivo da viabilidade de eritrócitos suínos estocados para estabelecer um modelo experimental de transfusão homóloga de hemácias: estudo piloto / In vitro and in vivo validation of stored swine erythrocyte viability to establish an experimental model of homologous red blood cell transfusion: a pilot study

Objetivo: Para desenvolver modelos experimentais de transfusão de hemácias, o primeiro passo é assegurar a viabilidade dos eritrócitos transfundidos. Avaliamos a viabilidade de eritrócitos transfundidos com validação in vitro e in vivo de eritrócitos suínos homólogos armazenados por 14 dias. Métodos: Neste estudo piloto, o sangue coletado de um suíno Agroceres® foi estocado em duas unidades de hemácias. A validação in vivo foi realizada pela marcação dos eritrócitos com Na2 51CrO4 e recuperação dos eritrócitos viáveis após 24 horas da infusão em um animal autólogo e quatro homólogos. A validação in vitro foi realizada na avaliação basal e após 14 dias, pela mensuração da hemoglobina, hematócrito, índice de hemólise e hemoglobina livre em seis unidades de hemácias. Foi realizada uma esplenectomia post-mortem para avaliar o sequestro esplênico de eritrócitos, e a radioatividade das amostras de sobrenadante foi contada para avaliar a hemólise intravascular. Resultados: Após 14 dias de estocagem, as unidades de hemácias tinham volumes menores e concentração total de hemoglobina equivalente em comparação aos padrões humanos. A concentração de hemoglobina livre aumentou de 31,0±9,3 para 112,4±31,4mg/dL (p<0,001) e o índice de hemólise aumentou de 0,1±0,1 para 0,5±0,1% (p<0,001). Entretanto, esses testes se encontravam dentro da faixa aceitável para os padrões humanos. A percentagem de radioatividade nas amostras de sobrenadante foi similar na avaliação basal e após 24 horas, afastando, assim, a presença de hemólise significante. Não se encontraram evidências de sequestro esplênico de eritrócitos radioativos. ...

Objective: To develop experimental models of erythrocyte transfusion, the first step is to ensure the viability of the red blood cells transfused. In this pilot study, we assessed the viability of transfused red blood cells with validation in vitro and in vivo of homologous swine erythrocytes stored for 14 days. Methods: Blood collected from one Agroceres® swine was stored in two red blood cell units. In vivo validation was performed by labeling the red blood cells with Na2 51CrO4 and recovering the viable erythrocytes after 24 hours of infusion in one autologous and four homologous animals. In vitro validation was performed at baseline and after 14 days in sixteen red blood cell units by measuring hemoglobin, hematocrit, hemolysis index and free hemoglobin. A post-mortem splenectomy was performed to evaluate the splenic sequestration of erythrocytes, and the radioactivity of the supernatant samples was counted to evaluate intravascular hemolysis. Results: After 14 days of storage, the red blood cell units had lower volumes and equivalent total concentrations of hemoglobin and hematocrit compared to human standards. The free hemoglobin concentration increased from 31.0±9.3 to 112.4±31.4mg/dL (p<0.001), and the hemolysis index increased from 0.1±0.1 to 0.5±0.1% (p<0.001). However, these tests were within the acceptable range for human standards. The percentage of radioactivity in supernatant samples was similar at baseline and after 24 hours, thus excluding significant hemolysis. No evidence of splenic sequestration of radioactive erythrocytes was found. Conclusion: Swine red blood cells stored for 14 days are viable and can be used in experimental studies of transfusion. These validation experiments are important to aid investigators in establishing experimental models of transfusion. .

A probable case of hepatitis B virus transfusion transmission revealed after a 13-month-long window period.

BACKGROUND: Transfusion-transmitted hepatitis B virus (HBV) infection in recipients with drug-related immunodeficiency is rarely described in endemic areas. Hepatitis B surface antigen (HBsAg)-negative infectious donor blood can be identified by sensitive nucleic acid testing (NAT). Two immunodeficient patients who received blood components from a single seronegative blood donor subsequently found to contain HBV DNA are described. MATERIALS AND METHODS: Multiple samples from the implicated donor and the two recipients were tested for HBV serologic and molecular markers. HBV genome fragments were amplified, sequenced, and phylogenetically analyzed. RESULTS: The implicated donation had low-level HBV DNA due to the donor being in the window period before the donor's seroconversion. Recipient 1 had been vaccinated to HBV and carried anti-HBs but remained negative for all other HBV markers until she developed acute hepatitis B (viral load 2.7 x 10(8) IU/mL and alanine aminotransferase [ALT] level 1744 IU/L) 13 months after transfusion of red cells. Identical HBV sequences from both donor and recipient provided evidence of transfusion-related infection. Recipient 2, who received platelets from the same donation while receiving major chemotherapy, remained uninfected. CONCLUSIONS: In unusual circumstances, HBV incubation time can be considerably prolonged. Both active and passive neutralizing antibodies to HBV likely delayed, but did not prevent, acute infection when the immune system was impaired. HBV NAT may have interdicted the infectious unit, although the donation viral load could not be quantified and odds of detection calculated.

Validação de um modelo experimental de transfusão de glóbulos vermelhos estocados homólogos em suínos e avaliação de seus efeitos cardiorrespiratórios e inflamatórios na hemorragia aguda / Validation of homologous stored red blood cell transfusion in swine and evaluation of cardiorespiratory and inflammatory effects in acute hemorrhage

Objetivos: Transfusão de sangue é fundamental para a sobrevida de pacientes selecionados, porém é associada a complicações. A literatura é controversa em relação aos efeitos pulmonares, hemodinâmicos e inflamatórios da transfusão de glóbulos vermelhos (GV). Este estudo teve dois objetivos principais: 1- validar um modelo de transfusão homologa de GV estocados em suínos com hipovolemia aguda por hemorragia controlada; 2- avaliar os efeitos agudos da transfusão de GV nas trocas gasosas, mecânica respiratória, hemodinâmica e na resposta inflamatória pulmonar e sistêmica. Métodos: Este estudo foi dividido em duas etapas: 1.Coleta, processamento e estocagem por 14 dias de GV provenientes de um suino Agroceres®, avaliado antes (in vitro) e após (in vivo - marcação com cromato de sódio radioativo) à sua transfusão em suínos sadios , um autólogo e quatro homologos (n=cinco); 2. Outro grupo de suínos foi submetido à hemorragia aguda controlada (25% de sua volemia) e então dividido em dois grupos: grupo transfusão (n= oito) recebeu duas unidades de GV e solução de ringer lactato (RL) para restabelecer a volemia; grupo controle (n=oito) que recebeu somente RL. Ambos os grupos foram seguidos até 6horas após o final da ressuscitação volêmica. Dados hemodinâmicos e respiratórios foram coletados a cada hora após o inicio do estudo. Mediadores inflamatórios e expressão de RNAmensageiro(RNAm) foram medidos no plasma e no tecido pulmonar. Resultados: Houve recuperação de 97,5%±19% dos GV marcados com cromato de sódio radioativo 24 horas após a transfusão. Houve aumento significativo da saturação venosa mista, conteúdo arterial de oxigênio e dos níveis de hemoglobina e hematócrito no grupo transfundido comparado ao controle. Os parâmetros medidos para a avaliação da microcirculação e as trocas gasosas foram similares em ambos os grupos. Observou-se um aumento significativo na energia gasta na histerese pulmonar no grupo controle quando comparado ao grupo transfundido (p=0,002),...

Objectives: Blood transfusion is critical to the survival of selected patients, but may be associated with complications. Previous data related to pulmonary, hemodynamic and inflammatory effects of red blood cells (RBC) are still controversial. This study has two main objectives: 1- Validate a homologous stored red blood cell transfusion model in swine with acute hypovolemia by controlled bleeding; 2- Assess the acute effects of RBC transfusion on gas exchange, respiratory mechanics and hemodynamics, pulmonary and systemic inflammatory response. Methods: This study was divided into two phases: 1. Collection, processing and storing RBC from Agroceres® swines for 14 days and evaluation before (in vitro) and after (in vivo - labelling with radioactive sodium chromate) transfusion in one autologous and four homologous healthy swines (n = five); 2. Controlled acute hemorrhage (25% of blood volume) of sixteen pigs and then allocation in two groups: transfusion group (n = eight) received two units of RBC and Lactaded Ringer's solution (RL) to restore blood volume; control group (n = eight) that received only LR. Both groups were followed up to 6 hours after the end of resuscitation. Hemodynamic and respiratory data were collected hourly after the start of the study. Inflammatory mediators and messenger RNA(mRNA) expression were measured in plasma and lung tissue. Results: The 24-hour recovery of RBC labeled with radioactive sodium chromate was 97.5% ± 19%. We found significant increase of mixed venous oxygen saturation, oxygen arterial content, and hemoglobin and hematocrit levels in the transfused group compared to control. There were no significant differences between the two groups in microcirculation and gas exchange. There was a significant increase in the energy spent in lung hysteresis in the control group compared to the transfused group (p=0,002), as well as a tendency to decrease inspiratory energy in the transfusion group. The...

Antígeno B adquirido: descriçäo de dois casos decorrentes de uso com anticorpos monoclonais derivados do clone ES4 / Acquired B Antigen: description of two cases due to monoclonal antibodies derived from ES4 clone

O fenômeno "B" adquirido consiste em uma modificaçäo do antígeno A pela açäo de enzimas bacterianas. Alguns reagentes monoclonais preparados a partir do clone ES4 säo conhecidos por detectar o antígeno "B" adquirido. A atividade deste antígeno é diminuída em meio de baixo pH. A correta interpretaçäo deste fenômeno é fundamental para evitarmos erros de tipagem sangüínea. O objetivo deste trabalho é a descriçäo de dois casos recentemente observados em nosso serviço. O primeiro refere-se a uma paciente de sexo feminino, 73 anos, com tumor de cólon e o segundo a uma paciente do sexo feminino, 63 anos, com Síndrome mielodisplásica e infecçäo urinária. As hemácias das pacientes foram analisadas contra dois soros anti-A, dois soros anti-B e dois soros anti-AB de procedências distintas e demonstraram resultados característicos ao grupo sanguíneo A, porém verificou-se reatividade com um dos soros anti-B monoclonais utilizados. Diante disto, as hemácias foram analisadas contra um painel de soros anti-B e nos casos reativos, o soro foi acidificado (pH=6,0) para confirmaçäo diagnóstica. Dos painéis de soros anti-B analisados, quatro soros apresentaram reatividade. Todos os soros perderam a reatividade ao serem acidificados. Dos seis soros anti-B reativos, cinco foram fabricados a partir do clone ES4. Portanto, concluímos tratar-se de dois casos do fenômeno "B" adquirido utilizando reagentes produzidos a partir do clone ES4, mostrando a importância da avaliaçäo dos reagentes utilizados na rotina em serviços hemoterápicos, bem como da avaliaçäo detalhada das propriedades, métodos e limitaçöes de cada reagente.